Skip to Content
 

News: Precision Cancer Medicine

Study identifies targeted therapy’s cardiac risks

Thursday, October 3rd, 2019

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

Expert Q&A: Understanding a new approach to cancer treatment

Saturday, June 29th, 2019

Precision oncology expert Dr. Ben Ho Park sheds light on cancer treatment innovations.

Study reframes approach to targeted therapy resistance

Thursday, April 25th, 2019

A recent study provides clinicians genomic guidance for surveillance of targeted therapy resistance in patients with EGFR-mutant non-small cell lung cancer — and more importantly — another drug option when resistance occurs.

GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment

Wednesday, January 16th, 2019

GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies.

Precision radiation aids patient’s cancer battle

Wednesday, December 12th, 2018

Precision radiation therapy helped treat patient Imogene Stranch’s cancer.

Connecting an asthma gene to leukemia

Friday, August 3rd, 2018

A receptor previously implicated in asthma may also play roles in other allergic diseases and in leukemia, Vanderbilt researchers have discovered.

Lung cancer patients and advocates visit VUMC research labs

Friday, June 15th, 2018

A group of young lung cancer patients and their family members recently toured research laboratories to learn how investigators are working to find better therapies and possibly a cure for the disease.

Park named to VICC breast cancer leadership position

Thursday, May 17th, 2018

Ben Ho Park, MD, PhD, has been named co-leader of the Breast Cancer Research Program, director of Precision Oncology and associate director for Translational Research at Vanderbilt-Ingram Cancer Center. He will assume his new post Sept. 1.

Looking beyond the ‘magic bullet’ approach to drug discovery

Thursday, May 3rd, 2018

Vanderbilt researchers have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature.

Wilkins takes key role in national ‘All of Us’ precision medicine effort

Monday, April 30th, 2018

Consuelo Wilkins, MD, MSCI, has been appointed director of a new Engagement Core to support the design, implementation and governance of the national All of Us Research Program, an ambitious effort led by the National Institutes of Health (NIH) to accelerate the prevention and treatment of illness through precision medicine.

Next Page »